Tick Boot Camp Podcast Por Matt Sabatello and Rich Johannesen arte de portada

Tick Boot Camp

Tick Boot Camp

De: Matt Sabatello and Rich Johannesen
Escúchala gratis

The goal of the Tick Boot Camp Podcast is to help people liberate themselves and others from suffering caused by Lyme disease through validation, community building, belief that healing is possible, and modeling success. Listen to our Tick Boot Camp podcast using all major podcast streaming services such as Apple Podcasts, Spotify, and YouTube Music. Our podcast is also integrated with smart home devices, such as Amazon Alexa and Apple TV. Ask your device to "play the Tick Boot Camp Podcast!"Copyright 2025 Enfermedades Físicas Higiene y Vida Saludable Medicina Alternativa y Complementaria
Episodios
  • Episode 558: Persistent Infection, Molecular Mimicry, and the Future of Chronic Lyme | Amy Proal, PhD

    Episode 558: Persistent Infection, Molecular Mimicry, and the Future of Chronic Lyme | Amy Proal, PhD
    Mar 14 2026
    In this powerful and science-forward episode of the Tick Boot Camp Podcast, host Matt Sabatello sits down with Amy Proal, PhD, a leading microbiologist whose work is reshaping how the medical community understands chronic Lyme disease, post-treatment Lyme disease (PTLD), ME/CFS, and Long COVID. Dr. Proal brings a rare combination of deep scientific expertise, lived experience with chronic illness, and real-world clinical integration, offering listeners clarity on why so many patients remain sick long after standard treatment ends — and what science is finally doing about it. 👩‍🔬 About Amy Proal, PhD Amy Proal, PhD, is an internationally recognized microbiologist specializing in the molecular mechanisms by which persistent pathogens alter human immunity, metabolism, and gene expression. She currently serves in two major leadership roles: President & Research Director, PolyBio Research Foundation Scientific Director, Cohen Center for Recovery from Complex Chronic Illness (CORE) at Mount Sinai Her work focuses on infection-associated chronic illness, including: Chronic Lyme disease & tick-borne co-infections Post-treatment Lyme disease syndrome (PTLD) ME/CFS Long COVID Dr. Proal is widely known for helping shift the scientific narrative away from psychosomatic explanations and toward biological root causes driven by persistent infection and immune dysregulation. 🧬 PolyBio Research Foundation: Rewriting the Science of Chronic Illness Dr. Proal co-founded PolyBio Research Foundation in 2018 alongside neuroscientist Dr. Michael VanElzakker, after recognizing that most chronic illness research ignored root cause biology, particularly infection. What Makes PolyBio Different Led by scientists, not administrators Focused on tissue-based research, not just blood tests Actively recruits researchers from HIV, tuberculosis, and virology fields to study Lyme and ME/CFS Designs research programs before fundraising, ensuring scientific rigor PolyBio has played a major role in advancing research on: Pathogen persistence in human tissue Hidden reservoirs of infection Why standard diagnostics often fail 🏥 Cohen Center for Recovery from Complex Chronic Illness (CORE) Dr. Proal also serves as Scientific Director of the Cohen Center for Recovery from Complex Chronic Illness (CORE) at Mount Sinai in New York City. CORE’s Mission Treat patients with Long COVID and chronic tick-borne illness within an insurance-based system Integrate clinical care with active research and clinical trials Establish new standards of care for infection-associated chronic disease At CORE, Dr. Proal helps design studies that leverage real patient visits — asking critical questions such as: Where is the pathogen hiding? What tissues are affected? What immune pathways are disrupted? 🧠 Persistent Infection & Why Blood Tests Fail A central theme of the episode is that chronic infection is often a tissue-based disease, not a blood-based one. Dr. Proal explains: Pathogens like Borrelia (Lyme) and SARS-CoV-2 actively avoid the bloodstream Blood is heavily patrolled by immune cells — tissue offers protection Absence of evidence in blood ≠ absence of infection This helps explain why: Lyme disease often goes undetected by standard serology Patients remain symptomatic despite “negative tests” Tissue biopsies and advanced imaging are essential for progress 🧬 Molecular Mimicry: How Infection Triggers Autoimmune Symptoms Dr. Proal provides a clear explanation of molecular mimicry, a key mechanism linking infection and autoimmunity. What Is Molecular Mimicry? Pathogens produce proteins that closely resemble human proteins The immune system attacks the pathogen — and accidentally attacks the body This creates autoimmune-like disease, even though infection is the trigger This mechanism helps explain: Why immune suppression may reduce symptoms but worsen disease Why many autoimmune diagnoses may actually be infection-driven Why treating the pathogen matters, not just calming the immune system 🔁 Successive Infection: Why Some Patients Get Sicker Than Others A major insight from this episode is Dr. Proal’s concept of successive infection. Rather than genetics alone, she suggests severity is often driven by: Prior infections (Lyme, Bartonella, Babesia, viruses) Environmental exposures (mold, toxins) Physical trauma (concussions, brain injury) Each “hit” dysregulates the immune system, making the next infection harder to clear — a cumulative burden that explains why: Some people become severely ill from Lyme Others remain asymptomatic despite repeated tick exposure 🧠 Neurological Lyme, the Brain & the Vagus Nerve Dr. Proal discusses multiple ways Lyme and infections affect the nervous system: Direct CNS Infection Pathogens crossing the blood–brain barrier Microglial activation causing neuroinflammation Indirect Neurological Signaling Infection in the gut, heart, or ...
    Más Menos
    1 h y 33 m
  • Episode 557: The Stanford Scientist Rewriting the Future of Lyme Disease Treatment — Dr. Jayakumar Rajadas | Tick Boot Camp

    Episode 557: The Stanford Scientist Rewriting the Future of Lyme Disease Treatment — Dr. Jayakumar Rajadas | Tick Boot Camp
    Mar 7 2026
    In this groundbreaking episode of the Tick Boot Camp Podcast, we interview Dr. Jayakumar Rajadas, a Stanford Medicine researcher who has discovered multiple breakthrough therapeutic candidates for Lyme disease, Babesia, and Bartonella. His work includes the discovery of Disulfiram’s effectiveness against Lyme and Babesia, Azlocillin’s potent activity against Lyme and Bartonella, and advanced targeted drug-delivery systems designed to preserve the gut microbiome. Dr. Jay's research has been featured in TIME Magazine (Azlocillin) and Forbes (Disulfiram), and connects deeply with the work of leading Lyme researchers, including Dr. Monica Embers (Tulane), Dr. Kim Lewis (Northeastern), Dr. Kenneth Liegner, and Dr. Brian Fallon (Columbia University). This interview delivers hope, science, and unprecedented detail on what may become the next generation of Lyme disease treatments. Key Topics Covered 1. How the Stanford Tick Initiative Sparked a New Era of Drug Discovery In 2012, Stanford launched a major initiative in response to community demand for better Lyme treatments. Dr. Rajadas was selected to lead drug development, focusing specifically on persistent/chronic Lyme disease, where few researchers were working. 2. Understanding Borrelia: Active vs. Stationary Forms & Why Chronic Lyme Persists Dr. J explains the three key survival modes of Borrelia burgdorferi: Active Phase The bacteria are replicating and metabolically active. Easier to kill with standard antibiotics. Stationary Phase Bacteria reach population limits and slow down growth. Represents early persistence mechanisms. Persister Forms Triggered by stressors like antibiotics (e.g., doxycycline). Bacteria fold into round bodies, spiral forms, or compact “cement-like” protective balls. These forms: Shut down metabolic pathways Resist penetration Survive antibiotic exposure Why Doxycycline Can Fail Doxycycline can induce persisters, causing Borrelia to form impenetrable protective shells rather than die. This is why many patients initially feel better, then relapse. 3. Disulfiram (Antabuse): Lyme + Babesia Breakthrough Featured in Forbes One of the biggest scientific shocks of the last decade: Discovery Through Stanford’s high-throughput screening of FDA-approved drugs, Disulfiram emerged as a top hit. Clears Borrelia (including persistent forms) Clears Babesia — a major advantage over standard antibiotics Does NOT harm the gut microbiome Is already FDA-approved and widely used for alcohol aversion therapy Highly potent but requires careful dosing due to side effects in inflamed patients. Why Some Patients Improve, and Others Suffer Chronic Lyme patients already have heightened inflammation. Disulfiram is a powerful molecule whose polymorphic forms behave differently in different people. His lab developed: Less toxic formulations Buccal & sublingual delivery systems Rectal delivery options These may reduce neuropsychiatric side effects reported by some patients. Clinical Connections Dr. Kenneth Liegner pioneered clinical use and published cases Dr. Brian Fallon conducted NIH-listed clinical trials. Many clinicians now use Liegner’s protocols. Real-world example: Matt shares the story of Brooke Stoddard (Generation Lyme), who regained his life after Disulfiram treatment under Dr. Liegner. 4. Azlocillin: The Antibiotic That TIME Magazine Called a Gamechanger If Disulfiram is the Lyme and Babesia weapon, Azlocillin may be the frontline tool for Lyme and Bartonella. Why Azlocillin Is Revolutionary Eradicates both active and persister forms of Borrelia. Destroys doxycycline-induced “cement ball” persisters by drilling into their vulnerable cell-wall synthesis pathways. Proven effective against Bartonella when paired with azithromycin, based on research by Dr. Monica Embers (Tulane) . The Cell-Wall Vulnerability Breakthrough Persisters STILL must maintain minimal cell-wall synthesis to survive. Azlocillin exploits this tiny vulnerability: It penetrates the protective sphere Breaks the “cement wall” Forces the bacteria out of hibernation Kills them rapidly This discovery is one of the biggest scientific leaps in Lyme research in a decade. The Delivery System That Protects the Gut Microbiome Azlocillin is extremely hydrophilic, making absorption difficult.Dr. Jay fixed this by creating: A magnesium-lipid nanoparticle formulation Designed to release in the upper intestine Avoiding the colon (where most microbiome lives) This allows: High bloodstream absorption Minimal microbiome damage Oral availability of a drug previously only available via IV Why Azlocillin May Be Better Than Disulfiram Hits Borrelia + Bartonella Stronger anti-inflammatory effects No polymorphism issues Fewer side effects Potent against persisters A company is preparing to bring his oral formulation to clinical trials by next year. 5. Loratadine (Claritin): The First Clue from 2012 Before Disulfiram and ...
    Más Menos
    1 h y 30 m
  • Episode 556: Solving Lyme Diagnostics and Discovering New Tick-Borne Pathogens with Dr. Bobbi S. Pritt

    Episode 556: Solving Lyme Diagnostics and Discovering New Tick-Borne Pathogens with Dr. Bobbi S. Pritt
    Feb 28 2026

    Dr. Bobbi S. Pritt joins Tick Boot Camp Podcast for a scientific deep dive into Lyme disease diagnostics, co-infections, and emerging tick-borne pathogens. Dr. Pritt is Professor and Chair of Laboratory Medicine and Pathology at Mayo Clinic and Director of the Clinical Parasitology Laboratory in Rochester, Minnesota. An internationally recognized expert in vector-borne diseases, she is globally known for discovering new tick-borne pathogens—including Borrelia mayonii and Ehrlichia muris eauclairensis—and for advancing cutting-edge molecular and metagenomic diagnostic testing used nationwide.

    This episode offers essential clarity for anyone navigating Lyme disease, unexplained symptoms, or confusing test results. Dr. Pritt explains why standard tests often miss early Lyme, how PCR and molecular tools can detect active infection, and what metagenomic sequencing may offer for more accurate and comprehensive diagnostics in the future.

    Episode Summary

    Dr. Pritt breaks down how Lyme and other tick-borne diseases are detected through antibody testing, PCR, tissue analysis, and cutting-edge molecular methods. She explains how her lab discovered multiple new pathogens in the upper Midwest, the role of tick species in disease transmission, and why co-infections complicate diagnosis. This conversation also explores geographic spread, climate change, tick behavior, and the strengths and limitations of today’s test algorithms.

    Key Topics

    • Discovery of Borrelia mayonii as a second cause of Lyme disease in the U.S.

    • Identification and characterization of Ehrlichia muris eauclairensis

    • Geographic hotspots and why the upper Midwest produces unique pathogens

    • Tick species differences: blacklegged vs. lone star ticks and their hunting strategies

    • Co-feeding in ticks and its role in pathogen evolution

    • Why early Lyme tests often return false-negative results

    • The science behind false positives and cross-reactivity

    • PCR advantages and limitations for detecting Borrelia

    • When skin biopsies can outperform blood tests

    • Differentiating Lyme, B. miyamotoi, Anaplasma, Babesia, and Powassan virus

    • When clinicians should order a full tick-borne disease panel

    • How climate and ecological changes drive new tick-borne threats

    • The promise of metagenomics and immune-signature diagnostics

    What You’ll Learn

    • Why current Lyme testing algorithms struggle in early infection

    • How new tick-borne pathogens are discovered and validated

    • Why lone star ticks are more aggressive and changing regional risk

    • When and why molecular testing is more effective

    • What symptoms point to co-infections needing additional testing

    • Why doxycycline is not effective for certain pathogens like Babesia

    • How metagenomic sequencing could identify every pathogen in a single sample

    • Where diagnostic innovation is heading and what patients can expect
    Más Menos
    Aún no se conoce
Todavía no hay opiniones